Análisis comparativo del tratamiento de la Obesidad mediante Farmacoterapia vs. Cirugía Bariátrica

The comparative analysis of obesity treatment using pharmacotherapy versus bariatric surgery highlights that this condition represents a growing public health challenge, requiring a comprehensive approach that combines lifestyle changes, psychological and nutritional support, and pharmacotherapy. Ph...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Gavilanez Marcatoma, Walter Orlando (author)
বিন্যাস: bachelorThesis
ভাষা:spa
প্রকাশিত: 2025
বিষয়গুলি:
অনলাইন ব্যবহার করুন:http://dspace.unach.edu.ec/handle/51000/15651
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
বিবরন
সংক্ষিপ্ত:The comparative analysis of obesity treatment using pharmacotherapy versus bariatric surgery highlights that this condition represents a growing public health challenge, requiring a comprehensive approach that combines lifestyle changes, psychological and nutritional support, and pharmacotherapy. Pharmacotherapy, although not the first option, plays a key role. Research is advancing in the development of new drugs that address different mechanisms of obesity. This descriptive and documentary study was based on academic sources such as PubMed, Google Scholar, Scielo, and Elsevier, using a qualitative and non-experimental approach. The results indicated that drugs such as orlistat, liraglutide, semaglutide, and the naltrexone-bupropion combination are effective in reducing weight and improving metabolic parameters. Semaglutide and tirzepatide, more recent drugs, have shown promising results, with weight losses of between 15% and 20%. However, its high cost and limited availability can restrict access. For its part, bariatric surgery has established itself as the most effective treatment for cases of severe obesity. Procedures such as gastric bypass and gastric sleeve allow for weight loss of over 80% and frequently achieve remission of associated comorbidities, such as type 2 diabetes. Combining surgery with GLP-1 agonists enhances the results and facilitates weight maintenance. The choice between pharmacotherapy and bariatric surgery should be based on the degree of obesity, the patient's clinical conditions, and their preferences.